A message from the Vioxx case [1]

American Journal of Health-System Pharmacy

Volumn 63, Issue 6, 2006, Pages 503-

  Baldwin, H John ^a   Droege, Marcus ^a   Daniel, Karen L ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

COST BENEFIT ANALYSIS; DECISION MAKING; DOCTOR PATIENT RELATION; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; LAW SUIT; LETTER; PATIENT RIGHT; PHARMACIST; PRESCRIPTION; PRIORITY JOURNAL; RESPONSIBILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TREATMENT REFUSAL;

EID: 33645070187     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050427     Document Type: Letter

References (3)

1. Berenson A. Jury calls Merck liable in death of man on Vioxx. NY Times. 2005; Aug 20.
2. Baldwin HJ. Providing medication information as a professional obligation. Am J Hosp Pharm. 1991; 48:77-8.
3. U.S. Food and Drug Administration. Vioxx (rofecoxib) questions and answers. www.fda.gov/cder/drug/infopage/vioxx/vioxxQA.htm (accessed 2005 Sep 14).